American biopharmaceutical company Neurocrine Biosciences recently acquired Diurnal, a UK-headquartered specialty pharmaceutical company dedicated to developing lifelong treatments for rare and chronic endocrine disorders and Myles Minter shared with MedCity News, a biotech industry trade publication, the implications for the company and it’s shareholders.
Equity Research
Myles Minter Analyzes Biotech Industry Acquisition in MedCity News
Delivered to Your Inbox
Stay up-to-date with the latest William Blair news and insights
Our Latest News
Storable Has Acquired Newbook
William Blair acted as the exclusive financial advisor to Storable, Inc., a portfolio company of EQT, in connection with its acquisition of Newbook, a portfolio company of Potentia Capital.
Read moreLeverage Loan Volume in Q1 Eclipses 2023
Q1 institutional loan volume hit its highest total since 2021, revitalizing leveraged finance markets after a humdrum 2023. With higher deal volume, anticipated rate cuts, and a more encouraging economic outlook, lenders are optimistic about the remainder of 2024.
Read moreJapan: 3 Key Healthcare Themes
Richard Reznick, Ph.D., discusses three key healthcare themes in Japan while on the ground in Tokyo.
Read more